Institut für Transfusionsmedizin und Immunhämatologie, Klinikum der Johann Wolfgang Goethe Universität, DRK-Blutspendedienst Baden-Württemberg - Hessen, Frankfurt/M., Germany ; Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, Frankfurt/M., Germany.
Transfus Med Hemother. 2013 Feb;40(1):32-5. doi: 10.1159/000345661. Epub 2013 Jan 3.
Xenotropic murine leukemia virus-related virus (XMRV) is a retrovirus that has recently been related to prostate cancers and chronic fatigue syndrome. Since other human-pathogenic retroviruses, such as HIV, human T-lymphotropic virus type I (HTLV-I) and -II, are known blood-transmitted pathogens, XMRV might present another hazard associated with products derived from in vitro cultures of human or animal origin, or blood component-based therapeutics. Here, we investigated whether XMRV was transmitted to individuals with hemophilia and frequent exposure to plasma-derived or recombinant clotting factors.
We used highly sensitive real-time PCR to test plasma samples from 127 consecutive individuals with hemophilia who consulted our hemophilia center either for treatment or for a standard check-up.
From the 127 hemophiliacs, 80 had prior contact to persons with either hepatitis B (n = 30), hepatitis C (n = 74) and/or HIV (n = 21), and 30 were currently being treated with plasma-derived and 97 with recombinant factor concentrates. None of the individuals tested positive for XMRV.
Independent of the ongoing discussion on whether the positive XMRV testing in initial reports was a result of reagent, sample, or tissue contamination, and whether XMRV is a real threat or a testing artifact, our data suggest that XMRV might not play an important role for hemophiliacs.
嗜异性鼠白血病病毒相关病毒(XMRV)是一种逆转录病毒,最近与前列腺癌和慢性疲劳综合征有关。由于其他人类致病性逆转录病毒,如 HIV、人类 T 淋巴细胞白血病病毒 I 型(HTLV-I)和 II 型,已知是血液传播的病原体,因此 XMRV 可能会带来与源自人或动物来源的体外培养物或血液成分治疗相关的另一种危害。在这里,我们研究了 XMRV 是否会传播给血友病患者和经常接触血浆衍生或重组凝血因子的人。
我们使用高度敏感的实时 PCR 检测了 127 名连续就诊于我们血友病中心的血友病患者的血浆样本,这些患者或因治疗或因标准检查而就诊。
在 127 名血友病患者中,有 80 名曾接触过乙型肝炎(n = 30)、丙型肝炎(n = 74)和/或 HIV(n = 21)患者,30 名正在接受血浆衍生治疗,97 名正在接受重组因子浓缩物治疗。没有一个个体检测到 XMRV 阳性。
无论最初报道中 XMRV 阳性检测是由于试剂、样本还是组织污染,以及 XMRV 是否是一个真正的威胁还是检测假象,我们的数据表明,XMRV 可能不会对血友病患者产生重要影响。